Patent intelligence · US
US 11571440
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
Patent details — US 11571440
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 7, 2023
- Expiration
- Feb 2, 2043
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Claims
- 17
- CPC classes
- A61K, A61K2039/5156, A61K2039/5158, A61K31/711
Quick answer
US 11571440 (Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Feb 7, 2023. Expires Feb 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K2039/5156, A61K2039/5158, A61K31/711, A61K39/0011, A61K45/06
More from Jazz Pharmaceuticals Ireland Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 11571440?
US 11571440 (Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Feb 7, 2023. Expires Feb 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11571440?
Jazz Pharmaceuticals Ireland Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 11571440 expire?
Our index shows an expiration date of Feb 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.